Fusion Antibodies Plc (GB:FAB) has released an update.
Richard Buick, the Chief Scientific Officer of Fusion Antibodies plc, has boosted his stake in the company with the purchase of 94,825 ordinary shares, bringing his total ownership to approximately 1.05% of the issued share capital. This move reflects confidence in the Belfast-based CRO, which is known for its antibody engineering services for therapeutic drugs and diagnostics, and operates in a rapidly growing monoclonal antibody therapeutics market expected to reach $445 billion by 2028.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
